Intech Investment Management LLC Has $12.51 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Intech Investment Management LLC reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.4% in the third quarter, Holdings Channel reports. The institutional investor owned 11,903 shares of the biopharmaceutical company’s stock after selling 3,240 shares during the period. Intech Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $12,513,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sachetta LLC increased its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the last quarter. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $26,000. Crewe Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $28,000. Finally, Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $745.48 on Friday. The firm has a market capitalization of $81.92 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 2.81 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a one year low of $735.95 and a one year high of $1,211.20. The company’s fifty day moving average price is $953.38 and its 200-day moving average price is $1,028.16.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Piper Sandler dropped their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Royal Bank of Canada lowered their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.